COMMUNIQUÉS West-GlobeNewswire

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals, Inc., Combination Therapy Offers the Potential of a Safer and More Effective Approach to a Wide Variety of Cancer Treatments
30/09/2019
SAN FRANCISCO, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that Kalos Therapeutics' lead compound, KTH-222, can produce a reduction in the attachment of [...]
Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations
30/09/2019
DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary [...]
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
30/09/2019
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Ambu A/S: Financial Diary
30/09/2019
Ambu Financial Diary 2019/20 and 2020/21 Attachment Company Announcement no 16 2018_19
MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress
30/09/2019
ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies
30/09/2019
- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million - ASLAN and Bukwang will co-own new entity to develop novel pre-clinical AhR [...]
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
30/09/2019
Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX [...]
NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER
30/09/2019
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER Paris & Boston, September 30, 2019 – 08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a [...]
NÉOVACS ANNONCE LA NOMINATION DE VINCENT SERRA EN QUALITÉ DE DIRECTEUR GÉNÉRAL
30/09/2019
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ANNONCE LA NOMINATION DE VINCENT SERRA EN QUALITÉ DE DIRECTEUR GÉNÉRAL Paris et Boston, le 30 septembre 2019 – 08h30 CEST - Néovacs (Euronext [...]
Aino Health AB (publ): Aino Health signs cooperation agreement with Monetra Oulu Oy
30/09/2019
Aino Health and Monetra Oulu Oy have signed a cooperation agreement in Finland where Monetra Oulu Oy will sell all of Aino’s services and connected implementation services. This cooperation supports Aino’s expansion [...]
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
30/09/2019
Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET ® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent [...]
OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade
30/09/2019
New data presented at the International Cancer Immunotherapy Conference (CICON) NANTES, France, Sept. 30, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) presented new data on its [...]
SPINEWAY : Spineway réalise une augmentation de capital de 1,3 M€
30/09/2019
Spineway réalise une augmentation de capital de 1,3 M€ SPINEWAY annonce la réalisation d’une augmentation de capital avec suppression du droit préférentiel de souscription au profit de la société d’investissements [...]
Change in number of shares and votes in Saniona AB (publ)
30/09/2019
PRESS RELEASE September 30, 2019 During September, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to conversion of convertible notes issued pursuant to the convertible notes [...]
Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15
30/09/2019
Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15 Saint-Herblain (France), September 30, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and [...]
Valneva: Recrutement terminé pour les études de Phase 2 du candidat vaccin contre la maladie de Lyme VLA15
30/09/2019
Valneva: Recrutement terminé pour les études de Phase 2 du candidat vaccin contre la maladie de Lyme VLA15 Saint-Herblain (France), 30 septembre 2019 –Valneva SE (“Valneva” ou “le Groupe”), société de biotechnologie [...]
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
30/09/2019
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program, which evaluates inhaled [...]
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
30/09/2019
Basel, Switzerland, September 30, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that a post-hoc analysis of efficacy data from a previously completed phase 1/2 study with its oncology drug candidate [...]
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
30/09/2019
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical development program, which [...]

Pages